select a format

Single User License
USD 2000 INR 129160
Site License
USD 4000 INR 258320
Corporate User License
USD 6000 INR 387480

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Dengue Fever-Pipeline Review, H1 2016

Dengue Fever-Pipeline Review, H1 2016


  • Products Id :- GMDHC8163IDB
  • |
  • Pages: 208
  • |
  • June 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Dengue Fever-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Dengue Fever-Pipeline Review, H1 2016', provides an overview of the Dengue Fever pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dengue Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dengue Fever and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Dengue Fever

The report reviews pipeline therapeutics for Dengue Fever by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Dengue Fever therapeutics and enlists all their major and minor projects

The report assesses Dengue Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Dengue Fever

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Dengue Fever

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Dengue Fever pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Dengue Fever Overview 9

Therapeutics Development 10

Pipeline Products for Dengue Fever-Overview 10

Pipeline Products for Dengue Fever-Comparative Analysis 11

Dengue Fever-Therapeutics under Development by Companies 12

Dengue Fever-Therapeutics under Investigation by Universities/Institutes 15

Dengue Fever-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Dengue Fever-Products under Development by Companies 20

Dengue Fever-Products under Investigation by Universities/Institutes 24

Dengue Fever-Companies Involved in Therapeutics Development 26

Abivax S.A. 26

Agilvax, Inc. 27

Altravax, Inc. 28

Arbovax, Inc. 29

BCI Pharma 30

Bioneer Corporation 31

Biotron Limited 32

CalAsia Pharmaceuticals, Inc. 33

Cocrystal Pharma, Inc. 34

Codagenix, Inc. 35

Emergent BioSolutions Inc. 36

Ennaid Therapeutics, LLC 37

GlaxoSmithKline Plc 38

Globavir Biosciences, Inc. 39

Hawaii Biotech, Inc. 40

Humabs BioMed SA 41

Immunotope, Inc. 42

Immunovaccine, Inc. 43

Inovio Pharmaceuticals, Inc. 44

Johnson & Johnson 45

Kineta, Inc. 46

Merck & Co., Inc. 47

Molplex Ltd. 48

NanoViricides, Inc. 49

Novartis AG 50

NovaTarg Therapeutics, Inc 51

Panacea Biotec Limited 52

ProtInhi B.V. 53

Sanofi Pasteur SA 54

Sarepta Therapeutics, Inc. 55

SIGA Technologies, Inc. 56

Takeda Pharmaceutical Company Limited 57

TechnoVax, Inc. 58

Themis Bioscience GmbH 59

VaxInnate Corporation 60

Visterra, Inc. 61

Dengue Fever-Therapeutics Assessment 62

Assessment by Monotherapy Products 62

Assessment by Target 63

Assessment by Mechanism of Action 65

Assessment by Route of Administration 67

Assessment by Molecule Type 69

Drug Profiles 71

ABX-220-Drug Profile 71

ABX-221-Drug Profile 72

Antisense RNAi Oligonucleotide for Dengue-Drug Profile 73

Antisense RNAi Oligonucleotide for Dengue-Drug Profile 74

BRM-211-Drug Profile 75

CDX-DENV-14-Drug Profile 76

celgosivir hydrochloride-Drug Profile 77

dengue (tetravalent) vaccine-Drug Profile 78

dengue (tetravalent) vaccine-Drug Profile 79

dengue (tetravalent) vaccine-Drug Profile 80

dengue (tetravalent) vaccine-Drug Profile 81

dengue (tetravalent) vaccine-Drug Profile 82

dengue (tetravalent) vaccine-Drug Profile 83

dengue (tetravalent) vaccine-Drug Profile 84

dengue (tetravalent) vaccine 4-Drug Profile 85

dengue (tetravalent) vaccines-Drug Profile 86

dengue (virus like particle) vaccine-Drug Profile 87

dengue (virus like particle) vaccine-Drug Profile 88

dengue [serotype 1] vaccine-Drug Profile 89

dengue [serotype 2] (monovalent) vaccine-Drug Profile 90

dengue [serotype 2] vaccine-Drug Profile 91

dengue [serotype 3] (monovalent) vaccine-Drug Profile 92

dengue [serotypes 1, 2, 3, 4] (tetravalent) vaccine-Drug Profile 93

dengue [serotypes 1, 2, 3, 4] (tetravalent) vaccine-Drug Profile 97

dengue [serotypes 1, 2, 3, 4] (tetravalent) vaccine-Drug Profile 98

dengue [serotypes 1, 2, 3, 4] (tetravalent) vaccine-Drug Profile 99

dengue [serotypes 1, 2, 3, 4] (tetravalent) virus like particle vaccine-Drug Profile 100

dengue [serotypes 1, 2] vaccine-Drug Profile 101

dengue [serotypes 1, 3, 4] (trivalent) vaccine-Drug Profile 102

dengue vaccine-Drug Profile 103

dengue vaccine-Drug Profile 105

dengue vaccine-Drug Profile 106

dengue vaccine-Drug Profile 107

dengue vaccine-Drug Profile 108

dengue vaccine-Drug Profile 109

DengueCide-Drug Profile 110

DV-2DeltaGVII-Drug Profile 112

DV-2DeltaLIG-Drug Profile 113

DV-2G460P-Drug Profile 114

FDX-000-Drug Profile 116

fenretinide-Drug Profile 117

FX-06-Drug Profile 118

GBV-001-Drug Profile 120

GBV-006-Drug Profile 121

GREDEN/V1-4-Drug Profile 122

KIN-1148-Drug Profile 123

KIN-1400-Drug Profile 124

LCTA-949-Drug Profile 125

LVM-142-Drug Profile 126

modipafant-Drug Profile 127

Monoclonal Antibodies for Dengue-Drug Profile 128

Monoclonal Antibodies to Target Virion, prM and E Proteins for Dengue-Drug Profile 129

Monoclonal Antibody for Dengue-Drug Profile 130

Monoclonal Antibody for Dengue-Drug Profile 131

Peptides for Infectious Diseases-Drug Profile 132

PY-2-Drug Profile 133

QR-211-Drug Profile 134

Recombinant Peptide to Inhibit Dengue Protease for Dengue-Drug Profile 135

RKP-00156-Drug Profile 136

RS-1137-Drug Profile 137

RS-1142-Drug Profile 138

RS-1145-Drug Profile 139

RS-930-Drug Profile 140

RS-961-Drug Profile 141

Small Molecule for Dengue-Drug Profile 142

Small Molecule for Dengue-Drug Profile 143

Small Molecule for Dengue-Drug Profile 144

Small Molecule to Inhibit NS2B-NS3 Protease for Dengue and West Nile Virus Infection-Drug Profile 145

Small Molecule to Inhibit NS4B for Dengue and Yellow Fever Virus Infections-Drug Profile 146

Small Molecule to Inhibit RNA Dependent RNA Polymerase for Dengue-Drug Profile 147

Small Molecule to Target Envelope Protein for Dengue-Drug Profile 148

Small Molecules for Dengue-Drug Profile 149

Small Molecules to Activate AMPK for Dengue-Drug Profile 150

Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections-Drug Profile 151

Small Molecules to Inhibit Furin for Dengue-Drug Profile 153

Small Molecules to Inhibit M Protein for Dengue-Drug Profile 154

Small Molecules to Inhibit NS3 Protease for Dengue and West Nile Virus Infections-Drug Profile 155

Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections-Drug Profile 156

Small Molecules to Inhibit Pan Polymerase for Dengue-Drug Profile 157

Small Molecules to Inhibit RNA Dependent RNA Polymerase for Dengue Virus Infections-Drug Profile 158

Small Molecules to Inhibit Serine Protease for Viral Infections-Drug Profile 159

Small Molecules to Target Envelope Protein for Dengue-Drug Profile 160

ST-148-Drug Profile 161

ST-324-Drug Profile 163

ST-610-Drug Profile 165

Synthetic Peptide for Dengue-Drug Profile 166

Synthetic Peptide for Dengue Virus and West Nile Virus Infections-Drug Profile 167

TAK-003-Drug Profile 168

TDEN-PIV-Drug Profile 171

TV-003-Drug Profile 172

TVX-005-Drug Profile 174

UV-4B-Drug Profile 175

V-180-Drug Profile 176

Viral PMO-X-Drug Profile 177

VIS-513-Drug Profile 178

Dengue Fever-Dormant Projects 180

Dengue Fever-Discontinued Products 185

Dengue Fever-Product Development Milestones 186

Featured News & Press Releases 186

Appendix 200

Methodology 200

Coverage 200

Secondary Research 200

Primary Research 200

Expert Panel Validation 200

Contact Us 200

Disclaimer 201

List of Figures

Number of Products under Development for Dengue Fever, H1 2016 17

Number of Products under Development for Dengue Fever-Comparative Analysis, H1 2016 18

Number of Products under Development by Companies, H1 2016 19

Number of Products under Investigation by Universities/Institutes, H1 2016 22

Comparative Analysis by Late Stage Development, H1 2016 24

Comparative Analysis by Clinical Stage Development, H1 2016 25

Comparative Analysis by Early Stage Products, H1 2016 26

Assessment by Monotherapy Products, H1 2016 69

Number of Products by Top 10 Targets, H1 2016 70

Number of Products by Stage and Top 10 Targets, H1 2016 70

Number of Products by Top 10 Mechanism of Actions, H1 2016 72

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 72

Number of Products by Routes of Administration, H1 2016 74

Number of Products by Stage and Routes of Administration, H1 2016 74

Number of Products by Top 10 Molecule Types, H1 2016 76

Number of Products by Stage and Top 10 Molecule Types, H1 2016 76

List of Tables

Number of Products under Development for Dengue Fever, H1 2016 17

Number of Products under Development for Dengue Fever-Comparative Analysis, H1 2016 18

Number of Products under Development by Companies, H1 2016 19

Number of Products under Development by Companies, H1 2016 (Contd..1) 20

Number of Products under Development by Companies, H1 2016 (Contd..2) 21

Number of Products under Investigation by Universities/Institutes, H1 2016 23

Comparative Analysis by Late Stage Development, H1 2016 24

Comparative Analysis by Clinical Stage Development, H1 2016 25

Comparative Analysis by Early Stage Development, H1 2016 26

Products under Development by Companies, H1 2016 27

Products under Development by Companies, H1 2016 (Contd..1) 28

Products under Development by Companies, H1 2016 (Contd..2) 29

Products under Development by Companies, H1 2016 (Contd..3) 30

Products under Investigation by Universities/Institutes, H1 2016 31

Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 32

Dengue Fever-Pipeline by Abivax S.A., H1 2016 33

Dengue Fever-Pipeline by Agilvax, Inc., H1 2016 34

Dengue Fever-Pipeline by Altravax, Inc., H1 2016 35

Dengue Fever-Pipeline by Arbovax, Inc., H1 2016 36

Dengue Fever-Pipeline by BCI Pharma, H1 2016 37

Dengue Fever-Pipeline by Bioneer Corporation, H1 2016 38

Dengue Fever-Pipeline by Biotron Limited, H1 2016 39

Dengue Fever-Pipeline by CalAsia Pharmaceuticals, Inc., H1 2016 40

Dengue Fever-Pipeline by Cocrystal Pharma, Inc., H1 2016 41

Dengue Fever-Pipeline by Codagenix, Inc., H1 2016 42

Dengue Fever-Pipeline by Emergent BioSolutions Inc., H1 2016 43

Dengue Fever-Pipeline by Ennaid Therapeutics, LLC, H1 2016 44

Dengue Fever-Pipeline by GlaxoSmithKline Plc, H1 2016 45

Dengue Fever-Pipeline by Globavir Biosciences, Inc., H1 2016 46

Dengue Fever-Pipeline by Hawaii Biotech, Inc., H1 2016 47

Dengue Fever-Pipeline by Humabs BioMed SA, H1 2016 48

Dengue Fever-Pipeline by Immunotope, Inc., H1 2016 49

Dengue Fever-Pipeline by Immunovaccine, Inc., H1 2016 50

Dengue Fever-Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 51

Dengue Fever-Pipeline by Johnson & Johnson, H1 2016 52

Dengue Fever-Pipeline by Kineta, Inc., H1 2016 53

Dengue Fever-Pipeline by Merck & Co., Inc., H1 2016 54

Dengue Fever-Pipeline by Molplex Ltd., H1 2016 55

Dengue Fever-Pipeline by NanoViricides, Inc., H1 2016 56

Dengue Fever-Pipeline by Novartis AG, H1 2016 57

Dengue Fever-Pipeline by NovaTarg Therapeutics, Inc, H1 2016 58

Dengue Fever-Pipeline by Panacea Biotec Limited, H1 2016 59

Dengue Fever-Pipeline by ProtInhi B.V., H1 2016 60

Dengue Fever-Pipeline by Sanofi Pasteur SA, H1 2016 61

Dengue Fever-Pipeline by Sarepta Therapeutics, Inc., H1 2016 62

Dengue Fever-Pipeline by SIGA Technologies, Inc., H1 2016 63

Dengue Fever-Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 64

Dengue Fever-Pipeline by TechnoVax, Inc., H1 2016 65

Dengue Fever-Pipeline by Themis Bioscience GmbH, H1 2016 66

Dengue Fever-Pipeline by VaxInnate Corporation, H1 2016 67

Dengue Fever-Pipeline by Visterra, Inc., H1 2016 68

Assessment by Monotherapy Products, H1 2016 69

Number of Products by Stage and Target, H1 2016 71

Number of Products by Stage and Mechanism of Action, H1 2016 73

Number of Products by Stage and Route of Administration, H1 2016 75

Number of Products by Stage and Molecule Type, H1 2016 77

Dengue Fever-Dormant Projects, H1 2016 187

Dengue Fever-Dormant Projects (Contd..1), H1 2016 188

Dengue Fever-Dormant Projects (Contd..2), H1 2016 189

Dengue Fever-Dormant Projects (Contd..3), H1 2016 190

Dengue Fever-Dormant Projects (Contd..4), H1 2016 191

Dengue Fever-Discontinued Products, H1 2016 192

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Abivax S.A.

Agilvax, Inc.

Altravax, Inc.

Arbovax, Inc.

BCI Pharma

Bioneer Corporation

Biotron Limited

CalAsia Pharmaceuticals, Inc.

Cocrystal Pharma, Inc.

Codagenix, Inc.

Emergent BioSolutions Inc.

Ennaid Therapeutics, LLC

GlaxoSmithKline Plc

Globavir Biosciences, Inc.

Hawaii Biotech, Inc.

Humabs BioMed SA

Immunotope, Inc.

Immunovaccine, Inc.

Inovio Pharmaceuticals, Inc.

Johnson & Johnson

Kineta, Inc.

Merck & Co., Inc.

Molplex Ltd.

NanoViricides, Inc.

Novartis AG

NovaTarg Therapeutics, Inc

Panacea Biotec Limited

ProtInhi B.V.

Sanofi Pasteur SA

Sarepta Therapeutics, Inc.

SIGA Technologies, Inc.

Takeda Pharmaceutical Company Limited

TechnoVax, Inc.

Themis Bioscience GmbH

VaxInnate Corporation

Visterra, Inc.

Dengue Fever Therapeutic Products under Development, Key Players in Dengue Fever Therapeutics, Dengue Fever Pipeline Overview, Dengue Fever Pipeline, Dengue Fever Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com